Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM3WP0N)

Drug Name

AL3818 Drug Info

Synonyms

Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-

Indication

Disease Entry	ICD 11	Status	REF
Alveolar soft part sarcoma	2A60-2C35	Phase 3	[1]
Leiomyosarcoma	2B58	Phase 3	[1]
Synovial sarcoma	2B5A	Phase 3	[1]
Cervical cancer	2C77.0	Phase 1/2	[1]
Endometrial cancer	2C76	Phase 1/2	[1]
Fallopian tube cancer	2C74	Phase 1/2	[1]
Ovarian cancer	2C73	Phase 1/2	[1]
Peritoneal cavity cancer	2C51.Z	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 25017411
CAS Number: CAS 1058156-90-3
TTD Drug ID: DM3WP0N
INTEDE Drug ID: DR1881

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	Highest Status	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Phase 3	[2]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Phase 3	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Proto-oncogene c-Src (SRC)	DTT	SRC	2.907	3.35	3.498	4.75
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	10.08	7.207	5.403	9.211
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	11.692	6.58	4.984	9.089

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Alveolar soft part sarcoma

ICD Disease Classification

2A60-2C35

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proto-oncogene c-Src (SRC)	DTT	SRC	6.45E-01	-0.08	-0.58
Proto-oncogene c-Src (SRC)	DTT	SRC	2.08E-03	-0.52	-1.62
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	7.76E-01	-2.05E-01	-5.72E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.78E-01	-1.22E-03	-4.10E-03
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	5.50E-01	-9.32E-02	-1.01E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.15E-08	-6.60E-01	-3.96E+00

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.